Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
SAN FRANCISCO, Feb. 02, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Natus Medical Incorporated (NASDAQ:BABY) to the securities class action lawsuit filed in the U.S. District Court for the Northern District of California and the March 31, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of BABY between October 16, 2015 and April 3, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/BABY
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On October 15, 2015, Natus announced it would supply the Venezuelan government with medical equipment, supplies and services over a three year period. The Company stated “[p]repayments totaling approximately $69 million are expected by the first quarter of 2016[]” and “[i]f fully performed, the total sales under the agreement would aggregate $232.5 million.”
However, by January 11, 2016, Natus had yet to receive a payment from the Venezuelan government and the Company reduced its fourth quarter 2015 revenue guidance from $102 - $105 million to approximately $100 million. That day, Natus’ stock closed at $38.25 per share, over 11% lower than the previous closing price of $43.20 per share.
By April 4, 2016, Natus announced it had again failed to secure any money from the Venezuelan government and the Company reduced its first quarter 2016 revenue guidance from $91.5 - $92.5 million to $87.5 million. Natus’ stock closed at $31.84 per share that day – down over 19%. SEC filings show the Company’s CEO (James Hawkins) and CFO (Jonathan Kennedy) together sold over $10.7 million of their shares between October and November 2015.
“Among other things, we’re concerned about insider selling, especially considering Defendants’ announcements and the Company’s twice-reduced guidance,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding BABY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
